| dc.creator | Murray,Nigel P. | |
| dc.date | 2018-01-01 | |
| dc.date.accessioned | 2019-05-02T21:22:45Z | |
| dc.date.available | 2019-05-02T21:22:45Z | |
| dc.identifier | https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-97602018000100503 | |
| dc.identifier.uri | http://revistaschilenas.uchile.cl/handle/2250/82782 | |
| dc.description | Abstract Minimal residual disease is that not detected by conventional imaging studies and clinically the patient remains disease free. However, with time these dormant cells will awaken and disease progression occurs, resulting in clinically and radiological detectable metastatic disease. This review addresses the concept of tumor cell dissemination from the primary tumor, the micrometastatic niche and tumor cell survival and finally the clinical utility of detecting and characterizing these tumor cells in order to guide management decisions in treating patients with prostate cancer. | |
| dc.format | text/html | |
| dc.language | en | |
| dc.publisher | Sociedad de Biología de Chile | |
| dc.relation | 10.1186/s40659-018-0180-9 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.source | Biological Research v.51 2018 | |
| dc.subject | Prostate cancer | |
| dc.subject | Circulating tumor cells | |
| dc.subject | Tumor cell dissemination | |
| dc.subject | Dormancy | |
| dc.subject | Micrometastasis | |
| dc.subject | Phenotype | |
| dc.subject | Treatment | |
| dc.title | Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management | |
